{"id":8487,"date":"2026-05-15T10:06:53","date_gmt":"2026-05-15T10:06:53","guid":{"rendered":"https:\/\/www.dsru.org\/?post_type=dsrunews&p=8487"},"modified":"2026-05-28T15:35:13","modified_gmt":"2026-05-28T15:35:13","slug":"challenges-in-monitoring-safety-of-glp-1-agonists","status":"publish","type":"dsrunews","link":"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/","title":{"rendered":"Challenges in monitoring safety of GLP-1 agonists"},"content":{"rendered":"\n

Our recent editorial<\/a> published in Drug Safety Journal describes the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) that are currently available for use in the UK, provides an overview of the safety profile of this drug class and considers how patients are currently accessing these medicines for weight management purposes in the UK. In particular, the scale of private prescribing is highlighted and the unique set of challenges this poses with respect to ongoing safety monitoring of these products is considered. With increasing numbers of people accessing these medicines privately, and the arrival of new formulations and new indications, the potential for medication errors, off-label use and contraindications is likely to increase.<\/p>\n\n\n\n

The editorial discusses how proactive monitoring of safety for these products could be achieved, including assessment of the effectiveness of additional risk minimisation measures.<\/p>\n\n\n\n

Davies M, H\u00e4rmark L. Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective. Drug Safety. Published online May 5, 2026. doi:10.1007\/s40264-026-01676-4<\/strong><\/p>\n\n\n\n

Read the paper in full here: https:\/\/rdcu.be\/fg3iq<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"featured_media":8490,"template":"","meta":{"_acf_changed":false},"categories":[4],"class_list":["post-8487","dsrunews","type-dsrunews","status-publish","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"\nGLP-1 Receptor Agonists Safety Monitoring | DSRU News<\/title>\n<meta name=\"description\" content=\"DSRU explores safety monitoring challenges linked to GLP-1 receptor agonists, including private prescribing, off-label use and medication errors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GLP-1 Receptor Agonists Safety Monitoring | DSRU News\" \/>\n<meta property=\"og:description\" content=\"DSRU explores safety monitoring challenges linked to GLP-1 receptor agonists, including private prescribing, off-label use and medication errors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/\" \/>\n<meta property=\"og:site_name\" content=\"DSRU\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DrugSafetyResearchUnit\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-28T15:35:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.dsru.org\/wp-content\/uploads\/2026\/05\/DSRU-Drug-Safety-Unit-News-600-x-450.jpeg.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@DSRUDrugSafety\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n\t<meta name=\"twitter:label2\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data2\" content=\"ashleigh barton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/dsrunews\\\/challenges-in-monitoring-safety-of-glp-1-agonists\\\/\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/dsrunews\\\/challenges-in-monitoring-safety-of-glp-1-agonists\\\/\",\"name\":\"GLP-1 Receptor Agonists Safety Monitoring | DSRU News\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/dsrunews\\\/challenges-in-monitoring-safety-of-glp-1-agonists\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/dsrunews\\\/challenges-in-monitoring-safety-of-glp-1-agonists\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.dsru.org\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/DSRU-Drug-Safety-Unit-News-600-x-450.jpeg.jpg\",\"datePublished\":\"2026-05-15T10:06:53+00:00\",\"dateModified\":\"2026-05-28T15:35:13+00:00\",\"description\":\"DSRU explores safety monitoring challenges linked to GLP-1 receptor agonists, including private prescribing, off-label use and medication errors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/dsrunews\\\/challenges-in-monitoring-safety-of-glp-1-agonists\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.dsru.org\\\/dsrunews\\\/challenges-in-monitoring-safety-of-glp-1-agonists\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/dsrunews\\\/challenges-in-monitoring-safety-of-glp-1-agonists\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/DSRU-Drug-Safety-Unit-News-600-x-450.jpeg.jpg\",\"contentUrl\":\"https:\\\/\\\/www.dsru.org\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/DSRU-Drug-Safety-Unit-News-600-x-450.jpeg.jpg\",\"width\":600,\"height\":450,\"caption\":\"DSRU Drug Safety Unit News - GLP-1 receptor agonists safety\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/dsrunews\\\/challenges-in-monitoring-safety-of-glp-1-agonists\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.dsru.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Challenges in monitoring safety of GLP-1 agonists\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#website\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/\",\"name\":\"DSRU\",\"description\":\"The UK\u2019s leading pharmacovigilance and pharmacoepidemiology unit.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#organization\"},\"alternateName\":\"Drug Safety Research Unit\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.dsru.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#organization\",\"name\":\"DSRU\",\"alternateName\":\"Drug Safety Research Unit\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.dsru.org\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/cropped-DSRU_Branding.png\",\"contentUrl\":\"https:\\\/\\\/www.dsru.org\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/cropped-DSRU_Branding.png\",\"width\":250,\"height\":115,\"caption\":\"DSRU\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dsru.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/DrugSafetyResearchUnit\",\"https:\\\/\\\/x.com\\\/DSRUDrugSafety\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/drug-safety-research-unit\\\/\",\"https:\\\/\\\/www.instagram.com\\\/drugsafetyresearchunit\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GLP-1 Receptor Agonists Safety Monitoring | DSRU News","description":"DSRU explores safety monitoring challenges linked to GLP-1 receptor agonists, including private prescribing, off-label use and medication errors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/","og_locale":"en_GB","og_type":"article","og_title":"GLP-1 Receptor Agonists Safety Monitoring | DSRU News","og_description":"DSRU explores safety monitoring challenges linked to GLP-1 receptor agonists, including private prescribing, off-label use and medication errors.","og_url":"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/","og_site_name":"DSRU","article_publisher":"https:\/\/www.facebook.com\/DrugSafetyResearchUnit","article_modified_time":"2026-05-28T15:35:13+00:00","og_image":[{"width":600,"height":450,"url":"https:\/\/www.dsru.org\/wp-content\/uploads\/2026\/05\/DSRU-Drug-Safety-Unit-News-600-x-450.jpeg.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@DSRUDrugSafety","twitter_misc":{"Estimated reading time":"1 minute","Written by":"ashleigh barton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/","url":"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/","name":"GLP-1 Receptor Agonists Safety Monitoring | DSRU News","isPartOf":{"@id":"https:\/\/www.dsru.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/#primaryimage"},"image":{"@id":"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/#primaryimage"},"thumbnailUrl":"https:\/\/www.dsru.org\/wp-content\/uploads\/2026\/05\/DSRU-Drug-Safety-Unit-News-600-x-450.jpeg.jpg","datePublished":"2026-05-15T10:06:53+00:00","dateModified":"2026-05-28T15:35:13+00:00","description":"DSRU explores safety monitoring challenges linked to GLP-1 receptor agonists, including private prescribing, off-label use and medication errors.","breadcrumb":{"@id":"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/#primaryimage","url":"https:\/\/www.dsru.org\/wp-content\/uploads\/2026\/05\/DSRU-Drug-Safety-Unit-News-600-x-450.jpeg.jpg","contentUrl":"https:\/\/www.dsru.org\/wp-content\/uploads\/2026\/05\/DSRU-Drug-Safety-Unit-News-600-x-450.jpeg.jpg","width":600,"height":450,"caption":"DSRU Drug Safety Unit News - GLP-1 receptor agonists safety"},{"@type":"BreadcrumbList","@id":"https:\/\/www.dsru.org\/dsrunews\/challenges-in-monitoring-safety-of-glp-1-agonists\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.dsru.org\/"},{"@type":"ListItem","position":2,"name":"Challenges in monitoring safety of GLP-1 agonists"}]},{"@type":"WebSite","@id":"https:\/\/www.dsru.org\/#website","url":"https:\/\/www.dsru.org\/","name":"DSRU","description":"The UK\u2019s leading pharmacovigilance and pharmacoepidemiology unit.","publisher":{"@id":"https:\/\/www.dsru.org\/#organization"},"alternateName":"Drug Safety Research Unit","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.dsru.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.dsru.org\/#organization","name":"DSRU","alternateName":"Drug Safety Research Unit","url":"https:\/\/www.dsru.org\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.dsru.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.dsru.org\/wp-content\/uploads\/2022\/01\/cropped-DSRU_Branding.png","contentUrl":"https:\/\/www.dsru.org\/wp-content\/uploads\/2022\/01\/cropped-DSRU_Branding.png","width":250,"height":115,"caption":"DSRU"},"image":{"@id":"https:\/\/www.dsru.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/DrugSafetyResearchUnit","https:\/\/x.com\/DSRUDrugSafety","https:\/\/www.linkedin.com\/company\/drug-safety-research-unit\/","https:\/\/www.instagram.com\/drugsafetyresearchunit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/dsrunews\/8487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/dsrunews"}],"about":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/types\/dsrunews"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/media\/8490"}],"wp:attachment":[{"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/media?parent=8487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dsru.org\/wp-json\/wp\/v2\/categories?post=8487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}